Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Stellar Biotechnologies (SBOT) Competitors

Stellar Biotechnologies logo

SBOT vs. AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, PYRGF, OSTX, ELYM, and ATNM

Should you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Eliem Therapeutics (ELYM), and Actinium Pharmaceuticals (ATNM).

Stellar Biotechnologies vs. Its Competitors

Stellar Biotechnologies (NASDAQ:SBOT) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Aerovate Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stellar Biotechnologies-1,782.64% -51.12% -48.37%
Aerovate Therapeutics N/A -90.19%-77.47%

Stellar Biotechnologies has higher revenue and earnings than Aerovate Therapeutics. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stellar Biotechnologies$210K246.45-$5.03M-$1.76-5.52
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.34

1.7% of Stellar Biotechnologies shares are owned by institutional investors. 7.8% of Stellar Biotechnologies shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Stellar Biotechnologies' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company Overall Sentiment
Stellar Biotechnologies Neutral
Aerovate Therapeutics Neutral

Summary

Stellar Biotechnologies beats Aerovate Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Stellar Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBOT vs. The Competition

MetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$51.75M$832.60M$5.76B$9.58B
Dividend YieldN/A4.84%4.41%4.10%
P/E Ratio-5.521.1731.1026.05
Price / Sales246.4526.34432.51103.82
Price / CashN/A19.5637.7358.48
Price / Book4.586.659.536.61
Net Income-$5.03M-$4.94M$3.26B$265.56M

Stellar Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBOT
Stellar Biotechnologies
N/A$9.71
+5.0%
N/A-8.4%$51.75M$210K-5.5225
AVTE
Aerovate Therapeutics
N/A$7.40
-1.2%
N/A-88.5%$214.49MN/A-2.4720Gap Up
High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$20.35
-4.1%
N/A-44.9%$191.25MN/A-6.5490High Trading Volume
CYBN
Cybin
2.4484 of 5 stars
$7.62
+5.0%
$85.00
+1,015.5%
N/A$179.52MN/A-1.7450News Coverage
Positive News
Analyst Revision
BIOA
BioAge Labs
N/A$4.50
+3.7%
N/AN/A$161.33MN/A0.00N/A
VIRI
Virios Therapeutics
N/A$4.77
-2.5%
$5.00
+4.8%
+2,256.9%$91.86MN/A-17.675
WHWK
Whitehawk Therapeutics
N/A$1.73
+2.4%
N/AN/A$81.54M$25.98M-28.8340
PYRGF
PyroGenesis Canada
N/A$0.28
+4.2%
N/A-63.8%$51.76M$9.14M-4.6090
OSTX
OS Therapies
2.232 of 5 stars
$1.78
+6.3%
$18.00
+914.1%
-39.8%$49.87MN/A-2.06N/AAnalyst Forecast
Gap Up
ELYM
Eliem Therapeutics
N/A$1.65
-2.9%
N/A-62.3%$49.09MN/A-3.119News Coverage
Positive News
ATNM
Actinium Pharmaceuticals
3.0107 of 5 stars
$1.52
+3.4%
$4.50
+196.1%
-14.1%$47.42MN/A-1.0930Positive News
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:SBOT) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners